Brief: Biocept Announces Agreement with Aegea Biotechnologies

Tauriga Sciences

06/08/2020 13:28

Aug 6 (Reuters) - Biocept Inc  BIOC.O :
    * BIOCEPT ANNOUNCES AGREEMENT WITH AEGEA BIOTECHNOLOGIES TO
DEVELOP NEW, HIGHLY SENSITIVE PCR-BASED COVID-19 ASSAY UTILIZING
PATENTED SWITCH-BLOCKER PCR TECHNOLOGY
    * BIOCEPT INC - COVID-19 PCR ASSAY IS BASED ON CORE
SWITCH-BLOCKER
TECHNOLOGY USED IN BIOCEPT'S SUITE OF ULTRA-SENSITIVE
ONCOLOGY-FOCUSED ASSAYS
    * BIOCEPT INC - BIOCEPT HAS FIRST OPTION TO NEGOTIATE A
LICENSE
AGREEMENT TO ANY RESULTING NEW COVID-19 PCR ASSAY FOR
COMMERCIALIZATION
    * BIOCEPT INC - INTELLECTUAL PROPERTY UNDERLYING
SWITCH-BLOCKER
TECHNOLOGY IS JOINTLY OWNED BY BIOCEPT AND AEGEA

Source text for Eikon:  ID:nPn35gqCma 
Further company coverage:  BIOC.O 

 ((Reuters.Briefs@thomsonreuters.com;))